Home Finance Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights – Yahoo Finance

Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights – Yahoo Finance

Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights – Yahoo Finance

– Completed Scientific Advice meeting with UK MHRA to support Phase 1/2a trial of CYB003 planned for mid-2022 –
– Company to host conference call at 8:30am EST today –
TORONTO, February 10, 2022–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", today reported unaudited financial results for its third quarter ended December 31, 2021.
"During the quarter, we continued to make tremendous progress advancing our proprietary psychedelic-based molecules toward clinical development – reaching regulatory milestones, completing numerous preclinical studies, and establishing reliable supply chains in the U.S. and the UK," said Doug Drysdale, Chief Executive Officer of Cybin. "Looking ahead, we believe that 2022 will be a pivotal year for Cybin with multiple therapeutic programs currently on track to enter clinical development that are supported by our promising and differentiated preclinical data. With patients always top of mind, we remain committed to our goal of developing accessible, safe, and effective treatments for mental illness, at a time when the need is greater than ever."
Recent Business and Pipeline Highlights:
Continued to advance CYB003 towards clinical development for the potential treatment of major depressive disorder ("MDD") and alcohol use disorder ("AUD"). The Company recently participated in a productive Scientific Advice Meeting with the UK Medical and Healthcare Products Regulatory Agency ("MHRA") to gain alignment and support on next steps for advancing its first-in-human Phase 1/2a trial of CYB003 for MDD into clinical development. Cybin plans to submit regulatory applications in the second quarter of CY2022, followed by initiation of the Phase 1/2a trial in mid-CY2022.
Completed more than 140 pre-clinical studies supporting the advancement of CYB003, CYB004, and other proprietary psychedelic molecules toward regulatory filings, marking more than 50 new preclinical studies completed in January 2022 alone and demonstrating Cybin’s commitment to progressing psychedelics into therapeutics and bringing these potential treatments to patients as quickly as possible.
Received U.S. patent for CYB004 confirming a key accomplishment in strengthening the Company’s IP portfolio. The patent covers CYB004, the Company’s proprietary deuterated dimethyltryptamine ("DMT") compound and a range of deuterated forms of DMT and 5-MeO-DMT and protects the CYB004 drug substance as a putative new chemical entity. Cybin plans to submit a regulatory application in the second quarter of CY2022 for a pilot study of CYB004, which is expected to begin in the third quarter of CY2022.
Cybin-sponsored Kernel Flow Phase 1 feasibility study received Institutional Review Board ("IRB") Approval. The feasibility study evaluating Kernel Flow, a wearable, quantitative neuroimaging technology, to measure ketamine’s psychedelic effects on hemodynamics in the cerebral cortex, is expected to begin in the first quarter of CY2022.
Announced Investigational New Drug ("IND") and IRB approvals for co-funded investigator-initiated Phase 2 clinical trial evaluating psychedelic-assisted psychotherapy utilizing the EMBARK psychedelic facilitator training program. The trial, which will be conducted at the University of Washington, will assess psychedelic-assisted psychotherapy with psilocybin treatment in frontline clinicians experiencing COVID-related distress and began enrolling in the fourth quarter of CY2021.
Awarded grant to support the first psychedelic treatment clinic at Lenox Hill Hospital, part of Northwell Health, to provide treatment for patients in underserved communities on the Upper East Side of Manhattan, New York.
Third-Quarter Financial Highlights
Cash and cash equivalents totaled to C$63.6 million as of December 31, 2021.
Cash-based operating expenses totaled C$12 million for the quarter ended December 31, 2021, of which C$2.5 million were one-time, non-recurring costs. Non-cash expenses totaled C$5.2 million for a net loss of C$17.2 million.
Conference Call and Webcast Details
DATE: Thursday, February 10, 2022
TIME: 8:30 a.m. (EST)
DIAL-IN 1-844-200-6205 (U.S. toll free) or 1-833-950-0062 (Canada toll free)
CODE 868712
WEBCAST https://events.q4inc.com/attendee/296855699
The live and archived webcast will also be available on the investor relations section of the Company’s website under the Events & Presentations page.
About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s development of innovative drug delivery systems, statements regarding the potential benefits of the Company’s novel deuterated psilocybin analog, CYB003, statements regarding the Company’s completion of preclinical studies of CYB003 in Q1 2022i and its plan to submit regulatory applications in the second quarter of CY2022, followed by initiation of the related Phase 1/2a trial in mid-CY2022, statements regarding the Company’s EMBARK Psychedelic Facilitator Training Program being conducted at the University of Washington, statements regarding the anticipated results of using Kernel Flow technology in the Company’s research and the expected commencement date of the feasibility study, and statements regarding submission of a clinical trial application for a pilot study of CYB004.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2021, the Company’s annual information form for the year ended March 31, 2021, and the Company's listing statement dated November 9, 2020, which are available under the Company's profile on www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward- looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward- looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.
Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
i Based on a calendar year-end.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220210005341/en/
Investor & Media:
Leah Gibson
Vice President, Investor Relations
Cybin Inc.
The Wilsonville company on Monday withdrew a registration statement it had filed in late December and told regulators that it “no longer wishes to conduct a public offering of securities at this time.” The company is spending heavily to build out production capacity in a rapid move to commercialize after a decade of research and development.
Affirm (AFRM) shares tanked and were briefly halted for volatility in the last hour of trading after the buy-now-pay-later company posted its quarterly results during market hours, following an errant tweet which revealed part of the print. The stock closed 21% lower, at $58.68.
After dropping steeply early Thursday morning, then recovering in the late morning, it's afternoon now, and Nvidia (NASDAQ: NVDA) stock is down again — by 2% as of 2:25 p.m. ET. It's not entirely clear what has investors upset with Nvidia, though. On the one hand,  Advanced Micro Devices (NASDAQ: AMD) just revealed that it has won some more business from Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL), which chose to use AMD EPYC processors to power Google Cloud's new "C2D virtual machine" offering.
Yahoo Finance's Jared Blikre reports Affirm earnings after they were released early due to a Twitter mistake.
U.S. stocks were deep in the red on Thursday as Wall Street weighed another decades-high inflation print and remarks by St. Louis Federal Reserve President James Bullard that signaled the central bank could intervene more aggressively than anticipated to tighten monetary conditions amid surging prices levels.
Shares of Affirm Holdings Inc. were plunging in Thursday afternoon trading after the buy-now pay-later company posted its latest earnings results more than an hour earlier than scheduled, showing higher-than-expected volume but a lower-than-anticipated revenue outlook.
Three months after a home-flipping initiative imploded in an embarrassing public display, Zillow Group Inc. reported better financial results than expected Thursday, including record revenue from selling the underwater homes
AT&T Inc. (NYSE:T) has been in a relative bear market possibly since 2017. The company took two major hits, including the March 2020 drop, and the WarnerMedia spinoff with Discovery, Inc (NASDAQ:DISC.A). Most retail shareholders were invested in AT&T because of the hefty historical dividend yield between 8.7% and 4.6% in the last decade. We will now evaluate how attractive will the future AT&T be for investors.
Aurora Cannabis Inc. shares gained in late trading Thursday, after the Canadian pot producer beat sales expectations for the first time in more than a year.
Cloudflare stock gained on December-quarter profit that met views while revenue topped estimates. Its 2022 revenue guidance came in above views.
Owning growth stocks is a great way to potentially boost your portfolio's gains, but knowing how to select the right companies that are poised to be long-term winners isn't always easy. To help you out with this process, I'm highlighting two growth stocks below — Upstart Holdings (NASDAQ: UPST) and Doximity (NYSE: DOCS) — that are not only well-positioned to grow in the short term, but that could also be fantastic stocks to hold over the next 10 years. If you've never heard of Upstart Holdings, the first thing you'll want to know is that this fast-growing tech company is a bet on the artificial intelligence (AI) loan-origination market.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of NIO Inc. ( NYSE:NIO…
Black Rifle Coffee Company CEO Evan Hafer joins Yahoo Finance Live to discuss the company going public via a SPAC merger on the New York Stock Exchange, building and expanding the coffee company across the nation, public perception, and the outlook for subscription-based businesses.
Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett is one of the world's greatest investors. Speaking strictly from a nominal basis, tech kingpin Apple (NASDAQ: AAPL) is, hands down, Buffett's greatest investment.
Honeywell's growth investments come at the expense of near-term profitability and cash flow, but they are set to be multi-billion-dollar businesses in a few years.
The REIT is "exploring its options," according to those in the know, and investors appear to think that will lead to good things.
Popular electric vehicle (EV) start-up Rivian Automotive (NASDAQ: RIVN) has gotten some extra publicity over the last couple of days. In early trading, Rivian stock plunged 6% before reversing that drop to a gain of about 4% as of 10:54 a.m. ET on Thursday.
Nvidia (NVDA) investors find themselves in uncharted territory in 2022. Despite clawing back some losses recently, the shares sit 11% into the red, and yet to fully recover from January’s bloodbath. Investors will be hoping that when the company delivers F4Q22’s (January quarter) report – after the bell on February 16 – Nvidia can once again bring the goods. While Susquehanna’s Christopher Rolland expects the chip giant to do so, he also thinks that as the stock has underperformed the SOX over t
Yahoo Finance's Jared Blikre reports earnings for Expedia and Zillow Group.
In this article, we discuss the 10 stocks that Mario Gabelli is selling. If you want to skip our detailed analysis of Gabelli’s history, investment philosophy, and hedge fund performance, go directly to Mario Gabelli is Selling These 5 Stocks. Mario Gabelli is an Italian-American investor and hedge fund manager who founded GAMCO Investors in […]



Please enter your comment!
Please enter your name here